Katia Donadello

Prof. Dr. Katia Donadello

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Critical Care Medicine
Verified
Journal Article
Closed access
DBDaniel De Backer
Daniel De Backer
KDKatia Donadello
Katia Donadello
YSYasser Sakr
Yasser Sakr
GOGustavo Ospina-Tascon
Gustavo Ospina-Tascon
DSDiamantino Salgado
Diamantino Salgado
JVJean-Louis Vincent
Jean-Louis Vincent
Objectives: Sepsis induces microvascular alterations that may play an important role in the development of organ dysfunction. However, the relationship of these alterations to systemic variables and outcome is still not well defined. We investigated which factors may influence microcirculatory alterations in patients with severe sepsis and whether these are independently associated with mortality. Design: Analysis of prospectively collected data from previously published studies by our group. Setting: A 36-bed, medicosurgical university hospital Department of Intensive Care. Patients: A total of 252 patients with severe sepsis in whom the sublingual microcirculation was visualized using orthogonal polarization spectral or sidestream darkfield imaging techniques. Measurements and Main Results: Microcirculatory measurements were obtained either early, within 24h of the onset of severe sepsis (n = 204), or later, after 48h (n = 48). When multiple measurements were obtained, only the first was considered. Although global hemodynamic variables were relatively preserved (mean arterial pressure 70 [65–77] mm Hg, cardiac index 3.3 [2.7–4.0] L/min.m2, and SvO2 68.3 [62.8–74.7]%), microvascular variables were markedly altered (proportion of perfused small vessels 65 [50–74]%, microvascular flow index 2.15 [1.80–2.60], and heterogeneity of proportion of perfused small vessels 35 [20–50]%). Among microcirculatory variables, proportion of perfused small vessels was the strongest predictor of outcome (receiver operating characteristic curve area 0.818 [0.766–0.871], p < 0.001). Survival rates decreased markedly with severity of alterations in the proportion of perfused small vessels (70% and 75% in the two upper proportion of perfused small vessel quartiles compared with 3% and 44% in the two lower quartiles, p < 0.0001). Multivariable analysis identified proportion of perfused small vessels and sequential organ failure assessment score as independent predictors of outcome. Microcirculatory alterations were less severe in the later than in the earlier (proportion of perfused small vessels, 74 [57–82]% vs. 63 [48–71]%, p = 0.004) phase of sepsis. In multivariable analysis focused on the early period of sepsis, proportion of perfused small vessels and lactate were independent predictors of outcome. Conclusions: Microcirculatory alterations are stronger predictors of outcome than global hemodynamic variables.

25 September 2013 in Virulence
Verified
Journal Article
Open access
DBDaniel De Backer
Daniel De Backer
DCDiego Orbegozo Cortes
Diego Orbegozo Cortes
KDKatia Donadello
Katia Donadello
JVJean-Louis Vincent
Jean-Louis Vincent
Multiple experimental and human trials have shown that microcirculatory alterations are frequent in sepsis. In this review, we discuss the various mechanisms that are potentially involved in their ...

11 March 2010 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
GOGustavo Ospina-Tascon
Gustavo Ospina-Tascon
ANAna Paula Neves
Ana Paula Neves
GOGiovanna Occhipinti
Giovanna Occhipinti
KDKatia Donadello
Katia Donadello
GBGustavo Büchele
Gustavo Büchele
DBDaniel De Backer
Daniel De Backer

1 August 2014 in Journal of Critical Care
Verified
Journal Article
Closed access
EAElio Antonucci
Elio Antonucci
EFEnrico Fiaccadori
Enrico Fiaccadori
KDKatia Donadello
Katia Donadello
FTFabio Silvio Taccone
Fabio Silvio Taccone
Federico FranchiFederico Franchi
Federico Franchi
SSSabino Scolletta
Sabino Scolletta

3 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
VBVincenzo Bronte
Vincenzo Bronte
SUStefano Ugel
Stefano Ugel
ETEliSA Tinazzi
EliSA Tinazzi
AVAntonio Vella
Antonio Vella
FSFrancesco De Sanctis
Francesco De Sanctis
OOOliviero Olivieri
Oliviero Olivieri
BACKGROUND. Patients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules. METHODS. We treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an observational, longitudinal trial and approved by the local ethics committee. The patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4 mg per day for the remaining 7 days. Changes in the immune phenotype and expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and correlated with serum-derived cytokine levels and antibodies against severe acute respiratory syndrome–coronavirus 2 (anti–SARS-CoV-2). In a single treated patient, we also evaluated the alteration of myeloid cell functional activity. RESULTS. We provide evidence that patients treated with baricitinib had a marked reduction in serum levels of IL-6, IL-1β, and TNF-α, a rapid recovery of circulating T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein, all of which were clinically associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired oxygen) ratio. CONCLUSION. These data suggest that baricitinib prevented the progression to a severe, extreme form of the viral disease by modulating the patients’ immune landscape and that these changes were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia. TRIAL REGISTRATION. ClinicalTrials.gov NCT04438629. FUNDING. This work was supported by the Fondazione Cariverona (ENACT Project) and the Fondazione TIM.

1 January 2011 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
DBDaniel De Backer
Daniel De Backer
KDKatia Donadello
Katia Donadello
Fabio Silvio TacconeFabio Silvio Taccone
Fabio Silvio Taccone
GTGustavo Adolfo Ospina Tascón
Gustavo Adolfo Ospina Tascón
DSDiamantino Salgado
Diamantino Salgado
JVJean-Louis Vincent
Jean-Louis Vincent
Multiple experimental and human trials have shown that microcirculatory alterations are frequent in sepsis. In this review, we discuss the characteristics of these alterations, the various mechanisms potentially involved, and the implications for therapy. Sepsis-induced microvascular alterations are characterized by a decrease in capillary density with an increased number of stopped-flow and intermittent-flow capillaries, in close vicinity to well-perfused capillaries. Accordingly, the surface available for exchange is decreased but also is highly heterogeneous. Multiple mechanisms may contribute to these alterations, including endothelial dysfunction, impaired inter-cell communication, altered glycocalyx, adhesion and rolling of white blood cells and platelets, and altered red blood cell deformability. Given the heterogeneous nature of these alterations and the mechanisms potentially involved, classical hemodynamic interventions, such as fluids, red blood cell transfusions, vasopressors, and inotropic agents, have only a limited impact, and the microcirculatory changes often persist after resuscitation. Nevertheless, fluids seem to improve the microcirculation in the early phase of sepsis and dobutamine also can improve the microcirculation, although the magnitude of this effect varies considerably among patients. Finally, maintaining a sufficient perfusion pressure seems to positively influence the microcirculation; however, which mean arterial pressure levels should be targeted remains controversial. Some trials using vasodilating agents, especially nitroglycerin, showed promising initial results but they were challenged in other trials, so it is difficult to recommend the use of these agents in current practice. Other agents can markedly improve the microcirculation, including activated protein C and antithrombin, vitamin C, or steroids. In conclusion, microcirculatory alterations may play an important role in the development of sepsis-related organ dysfunction. At this stage, therapies to target microcirculation specifically are still being investigated.